First Intraventricular Chemotherapy for Relapsed Pediatric brain tumor in Iran a Case Report

Babak Abdolkarimi¹, Hadi Digaleh², Parastou Ariana³, Maryam Ahmadi⁴, Mahdi Malekpour⁵, Fahimeh Golabi^6*

¹Associate Professor of Pediatric hematology Oncology department, Hakim children's, hospital, Tehran University of Medical Sciences, Tehran, Iran

²Assistant Professor of neurosurgery department, Hakim children's, hospital, Tehran University of Medical Sciences, Tehran, Iran

³Assistant Professor of anesthesilogy department, Hakim children's, hospital, Tehran University of Medical Sciences, Tehran, Iran

⁴Associate Professor of neurosurgery department, Hakim children's, hospital, Tehran University of Medical Sciences, Tehran, Iran

⁵Clinical research development center, Amir Oncology teaching hospital, Shiraz university of medical science, Shiraz, Iran

⁶Clinical research development center, Amir Oncology teaching hospital, Shiraz university of medical science, Shiraz, Iran

*Corresponding Author Fahimeh Golabi, Clinical Research Development Center, Amir Oncology Teaching Hospital, Shiraz University of Medical Science, Shiraz, Iran, E-mail: f.golabi9253@yahoo.com

Abstract

Medulloblastoma is an aggressive pediatric brain tumor with a high risk of recurrence and metastasis despite current multimodal treatments. Relapsed medulloblastoma is difficult to manage due to resistance to systemic chemotherapy and limited drug penetration through the blood-brain barrier. This case report presents a 6-year-old patient with relapsed medulloblastoma treated with intraventricular chemotherapy via an Ommaya reservoir in Iran. After failure of conventional chemotherapy, the patient received Methotrexate, Cytarabine, and Thiotepa directly into the cerebrospinal fluid. This report highlights the feasibility and potential benefits of intraventricular chemotherapy for relapsed medulloblastoma suggesting a valuable alternative therapeutic approach for this challenging condition.